The Myasthenia Gravis Foundation of America aims to establish connections, enhance lives, improve care, and ultimately find a cure for Myasthenia Gravis (MG). It supports groundbreaking research and clinical trials worldwide to discover new treatments and ways to live better with MG.
The Nancy Law Impact Award, created in honor of the former CEO and board chair of Myasthenia Gravis Foundation of America, supports high-impact clinical research and innovative scientific pilot studies aimed at improving the lives of people with MG and related neuromuscular junction disorders. The grant encourages proposals that focus on patient outcomes, changes in clinical or research practices, and the development of new investigations with the potential for federal, pharmaceutical, or private foundation support. Research priorities include biomarkers, mechanisms of disease, therapeutic strategies, improving patient outcomes, and pediatric treatment strategies. The MGFA commits to funding projects that address these priorities, along with other high-quality science outside of these areas, with up to $100,000 per year for a period of three years.